Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A.

Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11.

PMID:
31186238
2.

The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation.

Palangat M, Anastasakis DG, Fei DL, Lindblad KE, Bradley R, Hourigan CS, Hafner M, Larson DR.

Genes Dev. 2019 May 1;33(9-10):482-497. doi: 10.1101/gad.319590.118. Epub 2019 Mar 6.

PMID:
30842218
3.

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Wong HY, Sung AD, Lindblad KE, Sheela S, Roloff GW, Rizzieri D, Goswami M, Mulé MP, Ramos NR, Tang J, Thompson J, DeStefano CB, Romero K, Dillon LW, Kim DY, Lai C, Hourigan CS.

Front Oncol. 2019 Jan 15;8:669. doi: 10.3389/fonc.2018.00669. eCollection 2018.

4.

Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry.

Oetjen KA, Lindblad KE, Goswami M, Gui G, Dagur PK, Lai C, Dillon LW, McCoy JP, Hourigan CS.

JCI Insight. 2018 Dec 6;3(23). pii: 124928. doi: 10.1172/jci.insight.124928.

5.

Immunological effects of hypomethylating agents.

Lindblad KE, Goswami M, Hourigan CS, Oetjen KA.

Expert Rev Hematol. 2017 Aug;10(8):745-752. doi: 10.1080/17474086.2017.1346470. Epub 2017 Jul 3. Review.

Supplemental Content

Loading ...
Support Center